News & Updates
Filter by Specialty:
COVID-19 vaccine boosters effective against Omicron in people with substance use disorder
COVID-19 vaccine boosters provide protection against Omicron infection and related hospitalization among people with substance use disorder, researchers from the University of Hong Kong have reported.
COVID-19 vaccine boosters effective against Omicron in people with substance use disorder
29 May 2023
Vitamin D supplementation flops for TB prevention in children
A 3-year course of weekly oral vitamin D supplementation, while safe and effective at increasing serum 25(OH)D concentrations, does little to reduce the risk of contracting tuberculosis (TB) infection in children, as shown in the results of a phase III study.
Vitamin D supplementation flops for TB prevention in children
26 May 2023
Which COVID-19 vaccine should SARDs patients on immunomodulators use?
Vaccination with either BNT162b2 or mRNA-1273 results in a comparable risk of breakthrough COVID-19 infection among patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulatory medication, a study has shown.
Which COVID-19 vaccine should SARDs patients on immunomodulators use?
26 May 2023
COVID vax fortifies defences against emerging omicron variants in previously infected youths
For children and adolescents who have been previously exposed to SARS-CoV-2 infection, vaccination with BNT162b2 appears to provide additional protection against omicron BA.4 or BA.5 and XBB variant infections, according to a study from Singapore.
COVID vax fortifies defences against emerging omicron variants in previously infected youths
26 May 2023
Paediatric TB care riddled with uncertainty, study says
Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.
Paediatric TB care riddled with uncertainty, study says
25 May 2023
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
25 May 2023
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.